Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 28;387(4):374-376.
doi: 10.1056/NEJMc2206711. Epub 2022 Jun 29.

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Odile Launay  1 , Marine Cachanado  2 , Liem B Luong Nguyen  3 , Laetitia Ninove  4 , Marie Lachâtre  3 , Inès Ben Ghezala  5 , Marc Bardou  5 , Catherine Schmidt-Mutter  6 , Karine Lacombe  7 , Fabrice Laine  8 , Jean-Sébastien Allain  8 , Elisabeth Botelho-Nevers  9 , Marie-Pierre Tavolacci  10 , Christian Chidiac  11 , Patricia Pavese  12 , Bertrand Dussol  13 , Stéphane Priet  4 , Dominique Deplanque  14 , Amel Touati  2 , Laureen Curci  3 , Eleine Konate  3 , Nadine Ben Hamouda  15 , Anissa Besbes  15 , Eunice Nubret  16 , Florence Capelle  16 , Laurence Berard  2 , Alexandra Rousseau  2 , Eric Tartour  15 , Tabassome Simon  7 , Xavier de Lamballerie  4
Affiliations

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine

Odile Launay et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralizing Antibodies against Wild-type SARS-CoV-2 and the Beta, Delta, and Omicron BA.1 Variants at Days 0 and 15 after Receipt of a Third Vaccine Dose (Per-Protocol Population).
Shown are geometric mean titers (GMTs) of neutralizing antibodies against the original D614 (wild-type) strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the beta (B.1.351), delta (B.1.617.2), and omicron (B.1.1.529) BA.1 variants, as assessed at days 0 and 15 after the receipt of a third vaccine dose (booster). Participants who had received two doses of the BNT162b2 vaccine were randomly assigned to receive one of the following as a booster dose: the MVD614 vaccine (monovalent parental formulation), the MVB.1.351 vaccine (beta-adjuvanted formulation), or a third dose of the BNT162b2 vaccine. The per-protocol population included all the participants who underwent randomization and did not meet any of the exclusion criteria. The factor increases in each trial group are shown for the change from day 0 to day 15. 𝙸 bars indicate 95% confidence intervals, and circles the titers in individual participants. The dashed line represents the positivity threshold on the neutralization assay.
See this image and copyright information in PMC

References

    1. Rubin EJ, Baden LR, Morrissey S. Audio interview: do we need new Covid-19 vaccines? N Engl J Med 2022;386(18):e52-e52. - PubMed
    1. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:2258-2276. - PMC - PubMed
    1. Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022;386:1046-1057. - PMC - PubMed
    1. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med 2021;27:2025-2031. - PMC - PubMed

MeSH terms